Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...
In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million) in 2023. While cross-trial comparisons carry inherent ...
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who ...